President Urges Breaking Down Of Drug, Device Distinctions, Regulatory Barriers
This article was originally published in The Gray Sheet
Executive Summary
The White House held a summit on its Precision Medicine Initiative where President Obama emphasized the need to break down outmoded regulations, and suggested that the barriers between drug and device oversight need to be loosened. Also at the meeting: FDA and NIH announced new competitions and projects, including the launch of an effort to gather data from a million Americans over the next few years.
You may also be interested in...
FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
Friends of Cancer Research proposes realignment of FDA to be organized more around disease areas and less around the distinctions between drugs, devices and biologics. The idea has generated some support from former commissioners and current officials, while others warn of unintended consequences.
Precision Medicine Plan 'Golden Opportunity' For Device, Diagnostic Firms
A new proposed framework to realize President Obama's Precision Medicine Initiative has significant potential for device and diagnostic companies, according to NIH Director Francis Collins. He says it will give them a "competitive opportunity" to develop cheaper whole genome sequencing tests and open the door to other exciting technologies.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.